Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Shorla Gains FDA Nod for First Oral Liquid Version of Novartis' Gleevec
Details : Imkeldi (imatinib) oral solution is a kinase inhibitor, small molecule drug candidate which is indicated for the treatment of certain forms of leukemia and other cancers.
Product Name : Imkeldi
Product Type : Small molecule
Upfront Cash : Not Applicable
November 26, 2024
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methotrexate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shorla Gains FDA Approval for JYLAMVO™ Methotrexate in Pediatric Autoimmune Use
Details : Jylamvo is an anti-inflammatory oral methotrexate solution approved by FDA for the treatment of pediatric patients with acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis.
Product Name : Jylamvo
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : Methotrexate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shorla Oncology Gets FDA Approval for TEPYLUTE for Breast and Ovarian Cancer
Details : FDA has approved the NDA for alkylating agent, TEPYLUTE (thiotepa), a ready-to-dilute infusion formulation to treat breast and ovarian cancer.
Product Name : Tepylute
Product Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2024
Shorla Oncology Announces FDA Filing Acceptance for Leukemia Treatment
Details : SH-201 is the first palatable oral liquid chemotherapy in the U.S. for leukemia and certain cancers, designed to slow or stop disease growth.
Product Name : SH-201
Product Type : Small molecule
Upfront Cash : Not Applicable
April 08, 2024
Shorla Announces FDA Acceptance of NDA for New Treatment for Breast and Ovarian Cancer
Details : SH-105 is a ready-to-dilute form of a well-established drug that has been used as a freeze-dried powder. It is being evaluated for the treatment of breast and ovarian cancer.
Product Name : SH-105
Product Type : Small molecule
Upfront Cash : Not Applicable
January 09, 2024
Lead Product(s) : Methotrexate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Jylamvo (methotrexate) is a DHFR inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acute lymphoblastic leukemia in adults.
Product Name : Jylamvo
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 19, 2023
Lead Product(s) : Methotrexate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Therakind
Deal Size : Undisclosed
Deal Type : Acquisition
Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind
Details : Through the acquisition, Shorla gains Jylamvo, an oncology and autoimmune drug and easy-to-administer, sweet tasting oral methotrexate solution that eliminates the need for crushing or splitting pills, or compounding into a liquid formulation, for the US...
Product Name : Jylamvo
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
October 31, 2023
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Therakind
Deal Size : Undisclosed
Deal Type : Acquisition
Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio
Details : The financing will be used to accelerate the growth of its oncology portfolio by advancing its pipeline, including SH-105, bringing therapies to market that will address drug shortages, and improving the preparation and application of oncology medication...
Product Name : SH-105
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 04, 2023
Details : Under the agreement, Shorla will obtain an exclusive license from the developer to register and commercialize PIP-101, the first palatable oral solution of the related chemotherapeutic agent in the U.S. that slows or stops the growth of certain forms of ...
Product Name : PIP-101
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 06, 2023
Lead Product(s) : Nelarabine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Eversana
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nelarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older.
Product Name : Nelarabine-Generic
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 16, 2023
Lead Product(s) : Nelarabine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Eversana
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
